Core One Labs Inc.

CSE: COOL, OTC: CLABF, FRA: LD62, WKN:A2P8K3

Company Logo

Company Overview

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy.

Core One has developed a patent pending thin film oral strip (the "technology") which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability.

The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.

Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Financial Highlights

$2,913,586

Revenue (ttm)

-$2,827,303

Gross Profit (ttm)

-$1.42

Diluted EPS (ttm)

Management Team

Mr. Casey Fenwick
Pres

Mr. Brad Paul Eckenweiler
Founder & Advisor

Dr. John David Sanderson
Chief Science Officer & Director

Dr. Robert E.W. Hancock
Exec. Chairman

Mr. Joel Shacker
CEO & Director

Mr. Geoffrey Balderson
CFO & Sec.

Mr. Jan Burian Ph.D.
Chief Technical Officer

Dr. Elizabeth Matthews
Head of Scientific & Regulatory Affairs

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
59,738 (0%)

Insider Ownership
5%